U.S. stocks edge higher; solid earnings season continues
Investing.com - TD Cowen has reduced its price target on Bruker (NASDAQ:BRKR) to $40.00 from $47.00 while maintaining a Hold rating on the scientific instruments manufacturer. The stock, currently trading at a P/E ratio of 63.35x, has seen significant pressure lately, with InvestingPro data showing a 17.44% decline in the past week.
The price target adjustment follows Bruker’s reduction of its 2025 guidance after reporting weak results. The company’s stock closed down 9%, though it recovered somewhat from its early lows following the announcement. According to InvestingPro data, the stock is now trading near its 52-week low of $32.07, with seven analysts recently revising their earnings expectations downward.
TD Cowen noted that management is implementing "significant cost actions" designed to protect the company’s 2026 earnings per share amid the challenging market conditions.
The research firm characterized the current demand environment as "weak" with "low visibility" into future performance, factors that contributed to the guidance reduction and subsequent price target cut.
Despite these challenges, TD Cowen observed that investor interest in Bruker remains "fairly high" due to the stock’s valuation and the possibility that the company may be approaching a bottom in demand.
In other recent news, Bruker Corporation reported its earnings for the second quarter of 2025, which did not meet forecasts. The company announced an earnings per share (EPS) of $0.32, which was below the expected $0.42, representing a 23.81% shortfall. Additionally, Bruker’s revenue was reported at $797.4 million, slightly under the anticipated $812.81 million, marking a 1.9% revenue miss. Following these results, several financial firms adjusted their price targets for Bruker. Stifel reduced its price target from $48.00 to $40.00, maintaining a Hold rating, citing a mix of expected and unexpected factors affecting the company’s performance. JPMorgan lowered its target to $50.00 from $60.00 but kept an Overweight rating, noting Bruker’s relative success in 2023 and strong future guidance. Barclays (LON:BARC) also adjusted its target from $46.00 to $43.00 while maintaining an Overweight rating, following Bruker’s soft order numbers. These developments reflect the current challenges and outlook for Bruker in the financial markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.